{"id":3143,"date":"2015-02-09T07:30:00","date_gmt":"2015-02-09T07:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/settlement-between-xvivo-and-vivoline\/"},"modified":"2015-02-09T07:30:00","modified_gmt":"2015-02-09T07:30:00","slug":"settlement-between-xvivo-and-vivoline","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/settlement-between-xvivo-and-vivoline\/","title":{"rendered":"Settlement between XVIVO and Vivoline"},"content":{"rendered":"<\/p>\n

XVIVO Perfusion AB (publ) initiated legal proceedings, claiming the right to three patents\/patent applications owned by Vivoline Medical AB (publ) with regard to inventions made by Stig Steen. XVIVO Perfusion and Vivoline have now reached an agreement whereby, amongst other things, XVIVO Perfusion withdraws its claim at Lund District Court and compensates Vivoline for trial costs in the amount of approximately SEK 1.6 million. This sum will be charged to the first quarter of 2015. Through this agreement, the parties' differences in regard to the dispute have been definitively settled.<\/span><\/p>\n<\/p>\n

The settlement does not affect XVIVO Perfusion\u2019s current operations and strategy. The company's own products STEEN Solution\u2122, which is protected by patents granted until 2021 (in the US until 2022), and Perfadex\u00ae<\/sup> are not part of the underlying dispute which the settlement applies to.<\/span><\/p>\n<\/p>\n

February 9, 2015<\/span>
Gothenburg<\/span>
XVIVO Perfusion AB (publ)<\/span><\/p>\n

\n

For further information please contact:
<\/span>
Christoffer Rosenblad, CFO, +46 31\u00a0788 21 59, christoffer.rosenblad@xvivoperfusion.com<\/a><\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/a><\/span><\/p>\n

The information was submitted for publication on\u00a0February 9, 2015\u00a0at 8:30 a.m.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

XVIVO Perfusion AB (publ) initiated legal proceedings, claiming the right to three patents\/patent applications owned by Vivoline Medical AB (publ)…<\/p>\n","protected":false},"template":"","class_list":["post-3143","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"\nSettlement between XVIVO and Vivoline - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/settlement-between-xvivo-and-vivoline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Settlement between XVIVO and Vivoline - XVIVO\" \/>\n<meta property=\"og:description\" content=\"XVIVO Perfusion AB (publ) initiated legal proceedings, claiming the right to three patents\/patent applications owned by Vivoline Medical AB (publ)...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/settlement-between-xvivo-and-vivoline\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/settlement-between-xvivo-and-vivoline\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/settlement-between-xvivo-and-vivoline\\\/\",\"name\":\"Settlement between XVIVO and Vivoline - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2015-02-09T07:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/settlement-between-xvivo-and-vivoline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/settlement-between-xvivo-and-vivoline\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/settlement-between-xvivo-and-vivoline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Settlement between XVIVO and Vivoline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Settlement between XVIVO and Vivoline - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/settlement-between-xvivo-and-vivoline\/","og_locale":"en_US","og_type":"article","og_title":"Settlement between XVIVO and Vivoline - XVIVO","og_description":"XVIVO Perfusion AB (publ) initiated legal proceedings, claiming the right to three patents\/patent applications owned by Vivoline Medical AB (publ)...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/settlement-between-xvivo-and-vivoline\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/settlement-between-xvivo-and-vivoline\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/settlement-between-xvivo-and-vivoline\/","name":"Settlement between XVIVO and Vivoline - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2015-02-09T07:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/settlement-between-xvivo-and-vivoline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/settlement-between-xvivo-and-vivoline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/settlement-between-xvivo-and-vivoline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Settlement between XVIVO and Vivoline"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}